Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) Income from Continuing Operations (2023 - 2025)

Camp4 Therapeutics' Income from Continuing Operations history spans 3 years, with the latest figure at 12066000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 9.14% year-over-year to 12066000.0; the TTM value through Dec 2025 reached 50381000.0, up 2.39%, while the annual FY2025 figure was 50573000.0, 2.35% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 12066000.0 at Camp4 Therapeutics, up from 13228000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 12066000.0 in Q4 2025 and bottomed at 13559000.0 in Q4 2023.
  • The 3-year median for Income from Continuing Operations is 12575000.0 (2025), against an average of 12839222.22.
  • The largest YoY upside for Income from Continuing Operations was 9.14% in 2025 against a maximum downside of 1.16% in 2025.
  • A 3-year view of Income from Continuing Operations shows it stood at 13559000.0 in 2023, then rose by 2.06% to 13280000.0 in 2024, then increased by 9.14% to 12066000.0 in 2025.
  • Per Business Quant, the three most recent readings for CAMP's Income from Continuing Operations are 12066000.0 (Q4 2025), 13228000.0 (Q3 2025), and 12575000.0 (Q2 2025).